Product Pipeline
Lung cancer is the most common form of cancer in the world (12.3% of all cancers), with an estimated 2.2 million individuals diagnosed worldwide with lung cancer in 2020.
DO-1
DO-1 is a highly selective small molecule inhibitor of the MET kinase that was found to inhibit the organic cation transporter-2 (OCT-2).
DO-2
DeuterOncology’s lead product DO-2 is an improved MET kinase inhibitor, which is being developed as a potential ‘best in class’ targeted therapy for lung cancer.
